Phi Science

What Phi Science does

Phi Science is a Boston-based venture studio and lab founded in 2014 that builds tech-science startups from the earliest stages of scientific proof through a structured five-phase methodology (Discover, Decide, Build, Scale, Market-Ready). Rather than operating as a single product company, it functions as a parent to multiple portfolio companies spanning three verticals: Bionl (an AI-enabled no-code bioinformatics platform launched in 2024 with BioAgents for literature search and code generation, VAIC-aligned variant interpretation, and curated disease-specific patient cohorts), Obvios.ai (an AI-powered lung nodule detection platform using Vision Transformer models with PACS/DICOM integration for clinical radiology workflows), and Meddit (an evidence-based clinical decision support tool for physicians and researchers, distributed via web and mobile). Supporting the portfolio are Phi Digital (infrastructure and tooling) and Phi Education (founder training programs and Discord community).

The underlying technology stack spans multiple AI modalities — text-based generative AI and retrieval for literature/clinical questions, computer vision on CT imaging for nodule detection and longitudinal tracking, predictive analytics for variant classification, and process automation across genomic pipelines and imaging workflows. Compliance posture is enterprise-grade (HIPAA, GDPR, ISO 27001, SOC2), enabling hospital and pharma/biotech deployments. The studio employs 18 people split across portfolio companies and shared services, with named leadership including MD/PhD executives with 10–20+ years of biotech and clinical trial experience.

The business model is multi-layered: direct enterprise sales of bioinformatics and imaging platforms to hospitals, pharma, and biotech (Bionl, Obvios.ai); a self-serve PLG channel for Meddit via web and mobile; and a data commercialization pathway in which curated patient cohorts are monetized to pharmaceutical partners. Pricing is not publicly disclosed, no paying customers are named, and no revenue, funding rounds, or ownership details are disclosed.

Name

Phi Science

Website

https://phi.science

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Phi Science is a Boston-based venture studio founded in 2014 that builds AI-driven tech-science startups, operating portfolio companies Bionl (bioinformatics), Obvios.ai (lung nodule imaging), and Meddit (clinical decision support) for hospitals, pharma/biotech, physicians, and researchers.

Ownership category

akta.pro rank

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Distribution channels3 records

Marketing channels3 records

Core offering

Phi Science operates as a venture studio and lab that builds tech-science startups from early scientific proof, sustaining them through structured methodologies (Discover, Decide, Build, Scale, Market-Ready). Its portfolio includes Bionl, an AI-enabled no-code bioinformatics platform for clinical genomics; Obvios.ai, an AI-powered lung nodule detection and tracking system for clinical radiology; and Meddit, an evidence-based clinical decision support platform for physicians and researchers.

Product overview

Phi Science operates as a venture studio that builds, grows, and sustains tech-science startups across three portfolio companies: Bionl (AI-enabled no-code bioinformatics platform), Obvios.ai (AI-powered lung nodule detection), and Meddit (evidence-based clinical decision support). The portfolio spans Tech-bio, Healthcare, and AI & Technology sectors. Supporting infrastructure includes Phi Digital (tools and platforms) and Phi Education (founder training programs). The core product Bionl integrates BioAgents for AI-powered literature search and bioinformatics code generation, Bionl Notebook for collaborative analysis, and variant interpretation following international clinical guidelines.

Differentiator

Problem solved

Functional benefit

Brands

• Phi Digital: Digital arm that builds tools, platforms, and infrastructure powering the studio and broader tech-science ecosystem.
• Phi Education

Products and services

• Bionl AI-enabled no-code bioinformatics platform for research and clinical genomics that automates cloud, file system, data, and workflow management, featuring variant interpretation following international guidelines and disease-specific patient cohort curation for hospitals and pharma/biotech companies.
• Pan.bio End-to-end bioinformatics solution for research and clinical genomics, part of the Phi Science portfolio of tech-bio companies serving pharmaceutical and biotechnology companies.
• Obvios.ai AI-powered lung nodule detection and tracking platform built for clinical radiology workflows, featuring Vision Transformer-based CT scan analysis, multi-scan longitudinal tracking, 3D visualization, and PACS integration with DICOM-native output for hospital deployment.
• Meddit Evidence-based clinical decision support platform for physicians and researchers, providing AI-powered search across PubMed, general web content, and comprehensive medical literature to deliver rapid, technology-driven insights that reduce clinical decision time.
• Phi Education Training programs, workshops, and hands-on mentorship programs designed to develop the next generation of scientific founders within the Phi Science venture studio ecosystem.

Quantifiable outcome

• 40% Cost Reduction through localized AI-powered genomics
• +4 more outcomes

Segments6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability9 records

Feature5 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• PathAI: PathAI applies AI to pathology and diagnostics with pharma partnerships, comparable to Bionl's histopathology/radiology image support and pharma/biotech data commercialization angle.
• Aidoc: Aidoc is a clinical AI company specializing in radiology workflow and AI-assisted detection on CT imaging, directly competing with Phi Science's Obvios.ai lung nodule detection and PACS-integrated platform.
• Flagship Pioneering: Flagship Pioneering is a venture studio that creates and builds biotech and techbio companies from earliest-stage scientific concepts — the most direct analog to Phi Science's studio model and portfolio-company launch approach.
• Viz.ai: Viz.ai provides AI-powered clinical workflow and image analysis integrated with hospital PACS, serving as a direct competitor to Obvios.ai for radiology AI deployment in clinical settings.
• Owkin: Owkin applies AI to clinical research and patient data with pharma/biopharma partnerships, comparable to Bionl's AI-driven variant interpretation and disease-specific patient cohort commercialization for pharma clients.
• Petri: Petri is a venture studio building early-stage biotech startups from scientific founders, directly comparable to Phi Science's venture studio model in the techbio/biotech creation space.

Broad incumbents

• Tempus AI: Tempus AI is an established precision medicine company combining genomic sequencing, AI-based analytics, and clinical decision support — a broader incumbent overlapping with Phi Science's Bionl bioinformatics and Meddit decision support offerings.
• Schrodinger: Schrödinger provides computational biology and molecular simulation software used by pharma R&D; it is a broader incumbent in life-science software that overlaps with Phi Science's Bionl pipeline automation and BioAgents capabilities.
• Recursion Pharmaceuticals: Recursion is an AI-driven biotech combining high-throughput biology with machine learning, comparable as a techbio/AI-for-biology incumbent that overlaps with Phi Science's bioinformatics and AI experimentation thesis.

Emerging players

• BenchSci: BenchSci is an AI platform for biomedical research that uses machine learning to surface antibody and experimental data, intersecting with Phi Science's BioAgents literature/code-generation capabilities for scientists.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/phiscience

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phi Science